<DOC>
	<DOCNO>NCT00603941</DOCNO>
	<brief_summary>The Phase I/II study conduct open label , multiple center study CS-7017 , experimental drug paclitaxel chemotherapy subject advance anaplastic thyroid cancer . Biopsies obtain patient accessible tumor baseline , two-weeks first CS-7017 dosage ( prior start combination therapy ) end first study cycle ( week 3 combination therapy ) , order evaluate effect study drug alone combination chemotherapy agent tumor . Treatment continue disease progression development intolerable toxicity .</brief_summary>
	<brief_title>A Phase 1/2 Dose Finding Study Experimental New Drug CS7017 , Oral PPARγ Agonist Taken Mouth Twice Daily Combination With Paclitaxel Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>During Phase 1 Phase 2 portion study , subject eligibility criterion identical except prior treatment ATC . During Phase 1 , eligible subject may receive prior chemotherapy Phase 2 , eligible subject must chemotherapy naïve . Histologically cytologically diagnose , advance ATC Measurable lesion ( ) Lesion ( ) ( primary metastatic ) viable tumor tissue accessible repeat biopsy Age equal old 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Adequate organ bone marrow function Agreement use effective contraception treatment equal great 3 month end treatment Neither pregnant breastfeeding No medical history diabetes mellitus require treatment insulin oral agent ; pleural pericardial effusion clinically significant pulmonary cardiovascular disease . No clinically active brain metastasis , uncontrolled seizure disorder , spinal cord compression , carcinomatous meningitis No clinically significant active infection require antibiotic antiretroviral therapy No concomitant use TZDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Anaplastic Thyroid Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Tumor</keyword>
	<keyword>Anti-neoplastic Agent</keyword>
	<keyword>First-line treatment advance Anaplastic thyroid cancer</keyword>
</DOC>